Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.44 |
| ▸ | LCK | P06239 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495513 | 0.91 | NAMPT (0.51) | NAMPTMAPTBTKLCKKDR | |
| SCHEMBL12190206 | 0.90 | NAMPT (0.46) | NAMPTTP53MAPTTHRBBTK | |
| SCHEMBL2493799 | 0.90 | PRKAA2 (0.46) | NAMPTTP53MAPTTHRBBTK | |
| SCHEMBL2495544 | 0.88 | BTK (0.60) | BTKLCKKDRMAPK14BLK | |
| SCHEMBL2497141 | 0.85 | NAMPT (0.47) | NAMPTMAPTBTKLCKKDR | |
| SCHEMBL2497204 | 0.85 | BTK (0.46) | MAPTBTKLCKKDRMAPK14 | |
| SCHEMBL5997830 | 0.82 | TGM2 (0.52) | TP53MAPTCYP3A4KMT2AALDH1A1 | |
| SCHEMBL5995904 | 0.81 | MAPT (0.47) | TP53MAPTTHRBBTKLCK | |
| SCHEMBL5437747 | 0.80 | NAMPT (0.48) | NAMPTMAPTSTSALDH1A1 | |
| SCHEMBL5437752 | 0.80 | NAMPT (0.48) | NAMPTMAPTSTSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | NAMPT 1021/4885TP53 304/4885MAPT 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.